-
-
-
-
-
-
-
Immuneering reports 17.3-month survival in pancreatic cancer trial
-
-
-
-
-
-
-
Teva Pharma (TEVA) PT Raised to $45 at Truist Securities
-
-
-
-
-
-
-
FDA: 'The agency today is withdrawing final guidance titled “Scientific Considerations in Demonstrating Biosimilarity to a Reference Product'
-
-
-
-
-
-
-
Corcept Therapeutics stock falls after losing key patent case appeal
-
-
-
-
-
-
-
Teva Pharma (TEVA) Gets FDA Ok For aNDA For Ferric Citrate Anhydrous
-
-
-
-
-
-
-
Teva Pharma (TEVA) PT Raised to $37 at UBS
-
-
-
-
-
-
-
Increasing unusual put option volume: AMCR XIFR JCI HNGE MTSR GTM EWJ SLDP EWY ADMA TEVA
-
432,296 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

